Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
J Am Coll Cardiol
; 80(12): 1130-1143, 2022 09 20.
Article
in En
| MEDLINE
| ID: mdl-36050227
ABSTRACT
BACKGROUND:
Frailty is an increasingly common problem, and frail patients are less likely to receive new pharmacologic therapies because the risk-benefit profile is perceived to be less favorable than in nonfrail patients.OBJECTIVES:
This study investigated the efficacy of sacubitril/valsartan according to frailty status in 4,796 patients with heart failure with preserved ejection fraction randomized in the PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial.METHODS:
Frailty was measured by using the Rockwood cumulative deficit approach. The primary endpoint was total heart failure hospitalizations or cardiovascular death.RESULTS:
A frailty index (FI) was calculable in 4,795 patients. In total, 45.2% had class 1 frailty (FI ≤0.210, not frail), 43.5% had class 2 frailty (FI 0.211-0.310, more frail), and 11.4% had class 3 frailty (FI ≥0.311, most frail). There was a graded relationship between FI class and the primary endpoint, with a significantly higher risk associated with greater frailty (class 1 reference; class 2 rate ratio 2.19 [95% CI 1.85-2.60]; class 3 rate ratio 3.29 [95% CI 2.65-4.09]). The effect of sacubitril/valsartan vs valsartan on the primary endpoint from lowest to highest FI class (as a rate ratio) was 0.98 [95% CI 0.76-1.27], 0.92 [95% CI 0.76-1.12], and 0.69 [95% CI 0.51-0.95]), respectively (Pinteraction = 0.23). When FI was examined as a continuous variable, the interaction with treatment was significant for the primary outcome (Pinteraction = 0.002) and total heart failure hospitalizations (Pinteraction < 0.001), with those most frail deriving greater benefit.CONCLUSIONS:
Frailty was common in heart failure with preserved ejection fraction and associated with worse outcomes. Compared with valsartan, sacubitril/valsartan seemed to show a greater reduction in the primary endpoint with increasing frailty, although this was not significant when FI was examined as a categorical variable. (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Frailty
/
Heart Failure
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Am Coll Cardiol
Year:
2022
Type:
Article
Affiliation country:
Denmark